In Silico Screening of Novel Antimalarials Against Mutated DHFR and DHPS

Ian Oduori¹ and Brian Nguti^2,

¹Department of Pharmacy, China Pharmaceutical University, Nanjing, China

²Department of Pharmacy, Kabarak University, Nakuru, Kenya

Cite this paper:
Ian Oduori and Brian Nguti. In Silico Screening of Novel Antimalarials Against Mutated DHFR and DHPS. American Journal of Pharmacological Sciences. 2026; 14(2):20-26. doi: 10.12691/ajps-14-2-1

Abstract

Malaria continues to be a profoundly impactful infectious disease responsible for a significant number of fatalities annually, primarily attributed to Plasmodium falciparum. The onset of antifolate drug resistance, notably characterized by mutations in Plasmodium falciparum dihydrofolate reductase (pfDHFR) and Plasmodium falciparum dihydropteroate synthase (PfDHPS), has significantly undermined the effectiveness of current therapeutic interventions, highlighting the urgent need for the development of new inhibitory agents. This research delineates a thorough in silico methodology that employs structure-based virtual screening, ADMET profiling, and molecular docking analyses to discern promising lead compounds targeting pfDHFR. A collection of 400 synthetic compounds was evaluated against the quadruple-mutant (N51I+C59R+S108N+I164L) pfDHFR and triple mutant PfDHPS crystal structures (PDB: 1J3K and 6JWZ). Drug-likeness criteria grounded in Lipinski's Rule of Five and ADMET assessments were utilized to refine the selection of candidates. Molecular docking analyses were conducted employing AutoDock Vina, and binding affinities were compared with those of the reference antifolate compounds pyrimethamine, cycloguanil, and sulfadoxine. Five lead compounds — ZINC000019331645, ZINC000426406087, ZINC000001154555, ZINC000001160009, and ZINC000013283483 — exhibited exceptional binding energies between −8.0 and −8.5 kcal/mol, indicating stronger predicted binding than the three reference drugs. (sulfadoxine, pyrimethamine, cycloguanil). The findings indicate that the identified scaffolds are promising candidates for additional experimental validation as novel antimalarial drugs, relevant for addressing drug-resistant malaria.

Keywords:
Malaria Plasmodium falciparum Molecular Docking Virtual Screening Antifolate Resistance Drug Discovery AutoDock Vina; ADMET In Silico

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	“World malaria report 2025: Addressing the threat of antimalarial drug resistance”.
[2]	A. Mohanty, L. Carlos I, E. G. Barbosa, A. K. Jordão, and C. R. S. Garcia, “Targeting Plasmodium Falciparum Asexual and Sexual Stages with Melatonin-Based Indole Compounds,” ChemistrySelect, vol. 10, no. 41, p. e04720, 2025.
[3]	T. Masserey, L. Braunack-Mayer, R. S. Miller, J. J. Möhrle, and M. A. Penny, “A roadmap for understanding sulfadoxine-pyrimethamine in malaria chemoprevention,” Parasitology, vol. 152, no. 2, pp. 133–142, Feb. 2025.
[4]	“WHO guidelines for malaria, 13 August 2025,” 2025.
[5]	K. Verma et al., “Repurposing FDA‐approved drugs to target malaria through inhibition of dihydrofolate reductase in the folate biosynthesis pathway: A prospective approach,” J of Cellular Biochemistry, vol. 125, no. 3, p. e30533, Mar. 2024.
[6]	S. K. Halder et al., “Identification of potential inhibitors of dihydrofolate reductase (DHFR) through blocking the folate biosynthetic pathway of Mycobacterium tuberculosis utilizing structure-based virtual screening,” RSC Adv., vol. 15, no. 43, pp. 36331–36343, 2025.
[7]	R. T. Delfino, O. A. Santos-Filho, and J. D. Figueroa-Villar, “Molecular modeling of wild-type and antifolate resistant mutant Plasmodium falciparum DHFR,” Biophysical Chemistry, vol. 98, no. 3, pp. 287–300, Aug. 2002.
[8]	S. Ghosh, D. Joshi, C. S. Ponnusamy, B. Sridharan, and M. Velusamy, “Computational investigation of mutations in PfCRT and PfDHFR proteins for emerging resistance of Plasmodium falciparum to antimalarial drugs,” Molecular and Biochemical Parasitology, vol. 264, p. 111700, Dec. 2025.
[9]	C. Putaporntip, J. Somkuna, R. Rojrung, T. Tia, N. Kuamsab, and S. Jongwutiwes, “Contrasting evolutionary trajectories of pyrimethamine resistance in human and zoonotic malaria parasites,” Malar J, vol. 25, no. 1, p. 161, Mar. 2026.
[10]	A. Kaushik et al., “Antiprotozoal agents – Integration of drug discovery, medicinal chemistry, and advanced computational approaches: An in-depth review,” The Microbe, vol. 7, p. 100395, Jun. 2025.
[11]	W. Xu, “Current Status of Computational Approaches for Small Molecule Drug Discovery,” J. Med. Chem., vol. 67, no. 21, pp. 18633–18636, Nov. 2024.
[12]	L. P. Hastuti, F. Hermawan, M. R. Iresha, T. Ernawati, and Firdayani, “In-silico studies of hydroxyxanthone derivatives as potential pfDHFR and pfDHODH inhibitor by molecular docking, molecular dynamics simulation, MM-PBSA calculation and pharmacokinetics prediction,” Informatics in Medicine Unlocked, vol. 47, p. 101485, 2024.
[13]	J. Sim, D. Kim, B. Kim, J. Choi, and J. Lee, “Recent advances in AI-driven protein-ligand interaction predictions,” Current Opinion in Structural Biology, vol. 92, p. 103020, Jun. 2025.
[14]	S. S. Duay, R. C. Y. Yap, A. L. Gaitano, J. A. A. Santos, and S. J. Y. Macalino, “Roles of Virtual Screening and Molecular Dynamics Simulations in Discovering and Understanding Antimalarial Drugs,” International Journal of Molecular Sciences, vol. 24, no. 11, p. 9289, Jan. 2023.
[15]	P. V. T. Fokou et al., “Natural products as transmission-blocking agents against malaria: a comprehensive review of bioactive compounds and their therapeutic potential,” Malar J, vol. 24, no. 1, p. 164, May 2025.
[16]	E. Chikwaro, S. Nyoni, J. Ndlovu, and R. Shoko, “Natural products in antimalarial drug discovery: progress, emerging technologies, and future directions,” All Life, vol. 19, no. 1, p. 2634576, Feb. 2026.
[17]	P. J. P. Tjitda, F. O. Nitbani, T. D. Wahyuningsih, R. I. Lerrick, and Y. M. Abanit, “In Silico Study Revealing the Inhibitory Potential of Flavonoids From Azadirachta Indica against PfDHFR and PfDHODH as Antimalarial Agents,” ChemistrySelect, vol. 10, no. 19, p. e202404851, 2025.
[18]	“An Open Drug Discovery Competition: Experimental Validation of Predictive Models in a Series of Novel Antimalarials,” Journal of Medicinal Chemistry, vol. 64, no. 22, pp. 16450–16463, Nov. 2021.
[19]	J. Yuvaniyama et al., “Insights into antifolate resistance from malarial DHFR-TS structures,” Nat Struct Mol Biol, vol. 10, no. 5, pp. 357–365, May 2003.
[20]	I. V. Singh and S. Mishra, “Molecular Docking Analysis of Pyrimethamine Derivatives with Plasmodium falciparum Dihydrofolate Reductase,” Bioinformation, vol. 14, no. 5, pp. 232–235, 31 2018.
[21]	A. Ogunbowale and E. R. Georgieva, “Engineered Chimera Protein Constructs to Facilitate the Production of Heterologous Transmembrane Proteins in E. coli,” IJMS, vol. 25, no. 4, p. 2354, Feb. 2024.
[22]	M. E. Bragina, A. Daina, M. A. S. Perez, O. Michielin, and V. Zoete, “The SwissSimilarity 2021 Web Tool: Novel Chemical Libraries and Additional Methods for an Enhanced Ligand-Based Virtual Screening Experience,” International Journal of Molecular Sciences, vol. 23, no. 2, p. 811, Jan. 2022.
[23]	J. J. Naveja, M. Vogt, D. Stumpfe, J. L. Medina-Franco, and J. Bajorath, “Systematic Extraction of Analogue Series from Large Compound Collections Using a New Computational Compound–Core Relationship Method,” ACS Omega, vol. 4, no. 1, pp. 1027–1032, Jan. 2019.
[24]	N. Andayani and E. Mulatsari, “Molecular structure similarity analysis using Tanimoto coefficient and its correlation analysis with Maltase-glucoamylase inhibitory activity of Nigella sativa’s compounds,” JNPDD, vol. 2, no. 1, pp. 48–57, Sep. 2024.
[25]	A. Daina, O. Michielin, and V. Zoete, “SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules,” Sci Rep, vol. 7, no. 1, p. 42717, Mar. 2017.
[26]	N. Lohit et al., “Description and In silico ADME Studies of US-FDA Approved Drugs orDrugs under Clinical Trial which Violate the Lipinski’s Rule of 5,” LDDD, vol. 21, no. 8, pp. 1334–1358, Jun. 2024.
[27]	J. B. Baell and J. W. M. Nissink, “Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017—Utility and Limitations,” ACS Chem. Biol., vol. 13, no. 1, pp. 36–44, Jan. 2018.
[28]	D. E. V. Pires, T. L. Blundell, and D. B. Ascher, “pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures,” J. Med. Chem., vol. 58, no. 9, pp. 4066–4072, May 2015.
[29]	M. Zhao et al., “Cytochrome P450 Enzymes and Drug Metabolism in Humans,” IJMS, vol. 22, no. 23, p. 12808, Nov. 2021.
[30]	D. Gheidari, M. Mehrdad, and Z. Karimelahi, “Virtual screening, ADMET prediction, molecular docking, and dynamic simulation studies of natural products as BACE1 inhibitors for the management of Alzheimer’s disease,” Sci Rep, vol. 14, no. 1, p. 26431, Nov. 2024.
[31]	S. Kim et al., “PubChem 2025 update,” Nucleic Acids Research, vol. 53, no. D1, pp. D1516–D1525, Jan. 2025.
[32]	M. D. Hanwell, D. E. Curtis, D. C. Lonie, T. Vandermeersch, E. Zurek, and G. R. Hutchison, “Avogadro: an advanced semantic chemical editor, visualization, and analysis platform,” J Cheminform, vol. 4, no. 1, p. 17, Dec. 2012.
[33]	S. S. Butt, Y. Badshah, M. Shabbir, and M. Rafiq, “Molecular Docking Using Chimera and Autodock Vina Software for Nonbioinformaticians,” JMIR Bioinformatics Biotechnol, vol. 1, no. 1, p. e14232, Jun. 2020.
[34]	R. Agarwal and J. C. Smith, “Speed vs Accuracy: Effect on Ligand Pose Accuracy of Varying Box Size and Exhaustiveness in AutoDock Vina,” Molecular Informatics, vol. 42, no. 2, p. 2200188, Feb. 2023.
[35]	M. Feng, G. Heinzelmann, and M. K. Gilson, “Absolute binding free energy calculations improve enrichment of actives in virtual compound screening,” Sci Rep, vol. 12, no. 1, p. 13640, Aug. 2022.
[36]	U. Baroroh, S.Si., M.Biotek., Z. S. Muscifa, W. Destiarani, F. G. Rohmatullah, and M. Yusuf, “Molecular interaction analysis and visualization of protein-ligand docking using Biovia Discovery Studio Visualizer,” IJCB, vol. 2, no. 1, p. 22, Jul. 2023.